Body Composition and the Female Body After 40: Why Everything Changed — and What the Research Shows
A science-led guide to why body composition shifts after 40, the growth hormone connection, and what the research is exploring about Tesamorelin, CJC-1295, and Ipamorelin.
You did not stop trying. Your hormonal environment changed.
You are eating the same way. Training the same way. Sleeping — or trying to. And the body you are working with is redistributing itself in ways that do not respond to the effort you are putting in. Visceral fat accumulating around the midsection. Muscle that takes longer to build and disappears faster. A metabolism that no longer processes energy the way it used to.
This is the body composition shift of perimenopause and beyond — and it is not a willpower problem. It is a hormonal and metabolic reorganization driven by the decline of growth hormone, estrogen, and their downstream effects on fat metabolism, muscle protein synthesis, and body composition. Understanding the biology behind it changes what you ask and what you look for.
This guide covers why body composition changes after 40 at the hormonal level, what growth hormone decline actually means for fat and muscle, and what the research is exploring about three compounds — Tesamorelin, CJC-1295, and Ipamorelin — that target the specific mechanisms involved.
What is actually driving the shift after 40
Body composition after 40 is governed by a convergence of hormonal changes — none of which have to do with lack of effort. Each affects fat distribution, muscle maintenance, and metabolic rate through specific, documented mechanisms.
The growth hormone decline — somatopause
Growth hormone (GH) is produced by the pituitary gland in pulsatile bursts — primarily during deep sleep. It does not act directly on muscle or fat tissue. Instead, it signals the liver to produce IGF-1 (insulin-like growth factor 1), which is the primary driver of muscle protein synthesis, fat mobilization, and tissue repair.
GH production declines with age — a process called somatopause — with the most significant decline occurring between ages 30 and 60. The decline is not linear: it accelerates around the hormonal transition of perimenopause, compounding the effects of estrogen withdrawal on metabolism. When GH and IGF-1 are low, fat mobilization slows, muscle protein synthesis decreases, and visceral fat accumulates — regardless of diet or exercise effort.¹
Visceral fat — why it is different
Not all fat is the same. Subcutaneous fat — the fat under the skin — is metabolically less active and primarily a storage tissue. Visceral fat — the fat that accumulates around the abdominal organs — is metabolically active in ways that are directly harmful: it secretes inflammatory cytokines, disrupts insulin signaling, and contributes to cardiovascular disease risk and metabolic dysfunction.
Growth hormone has a particular affinity for visceral adipose tissue. GH receptors are highly expressed in visceral fat cells — when GH is adequate, lipolysis (fat breakdown) in visceral tissue is actively promoted. When GH declines, visceral fat becomes progressively resistant to mobilization through conventional diet and exercise. This is the biological basis of the stubborn midsection fat that many women notice specifically after 40.²
Muscle loss — sarcopenia
IGF-1 is the primary driver of muscle protein synthesis — the process by which muscle fibers are built and maintained. When IGF-1 declines alongside GH, muscle protein synthesis slows and protein breakdown increases relative to it. The result is progressive sarcopenia — the loss of muscle mass and function with age.
Sarcopenia matters beyond aesthetics. Muscle tissue is metabolically active — it is the primary site of glucose uptake in response to insulin, and its decline contributes directly to metabolic dysfunction, insulin resistance, and reduced physical capacity. Research has documented that muscle mass decline accelerates in the perimenopausal period, with estrogen loss compounding the effect of reduced GH and IGF-1.³
The estrogen connection
Estrogen directly influences body composition through multiple pathways: it promotes fat distribution away from visceral stores, supports insulin sensitivity, and has anabolic effects on muscle tissue. Its decline during perimenopause and menopause shifts fat distribution toward visceral accumulation, reduces insulin sensitivity, and removes a protective effect on muscle mass. The body composition changes of menopause are not simply the result of aging — they are specifically hormonal, which means they have hormonal mechanisms.⁴
What the research is exploring: Tesamorelin, CJC-1295, and Ipamorelin
Three compounds have generated significant research interest for their potential to address the growth hormone axis decline that drives body composition changes after 40. Each operates through a distinct mechanism within the hypothalamic-pituitary-GH-IGF-1 axis — and together they address different aspects of stimulating the body’s own GH production rather than replacing it externally.
An important distinction: these compounds stimulate the pituitary to produce its own growth hormone — they do not replace GH from the outside. This distinction matters because it preserves the pulsatile, self-regulating nature of GH secretion that exogenous GH injection disrupts.
Tesamorelin — the visceral fat specialist
Tesamorelin is a 44-amino acid synthetic analog of GHRH (growth hormone releasing hormone) — the signal your hypothalamus sends to the pituitary to trigger GH release. It is the most clinically validated compound in this cluster: it is FDA-approved under the name Egrifta for the treatment of HIV-associated lipodystrophy, specifically for reduction of excess visceral abdominal fat. This approval status means Tesamorelin has undergone rigorous clinical trials with documented human efficacy data.
| WHAT WE KNOW | Tesamorelin is FDA-approved for visceral fat reduction — giving it the strongest human clinical data foundation of any compound in this cluster. A 2010 New England Journal of Medicine study showed Tesamorelin reduced visceral adipose tissue by 18% over 26 weeks compared to placebo, with concurrent improvements in lipid profiles. It works by stimulating the pituitary’s own GHRH receptors, preserving pulsatile GH release rather than creating a constant non-physiological state. Research has shown improved IGF-1 levels, improved lipid profiles, and body composition changes in clinical populations. Unlike exogenous GH, Tesamorelin does not appear to significantly impair insulin sensitivity in clinical trial populations. |
| WHAT WE DON’T KNOW | The approved clinical use is specific to HIV-associated lipodystrophy — not general age-related body composition change. Research in perimenopausal and postmenopausal women for body composition optimization is limited. Long-term safety beyond the trial periods is not fully established in healthy aging populations. The IGF-1 elevation produced and its long-term implications require monitoring. Whether effects persist after cessation of use is not well characterized. |
| WHAT THAT MEANS | Tesamorelin is the most clinically grounded compound in this cluster for visceral fat reduction — FDA approval and published RCT data distinguish it from most peptides discussed in longevity contexts. The gap is the translation to the specific population of women navigating age-related body composition changes rather than HIV-associated lipodystrophy. The mechanism is directly relevant. The clinical evidence base is the most mature. |
CJC-1295 — the pituitary primer
CJC-1295 is a modified GHRH analog — a synthetic version of the signal that travels from the hypothalamus to the pituitary to trigger GH release. It comes in two versions with meaningfully different pharmacokinetics: CJC-1295 with DAC (drug affinity complex) has a half-life of approximately seven days due to albumin binding, creating sustained background GH stimulation. CJC-1295 without DAC has a half-life of 30-60 minutes, creating shorter, more physiologically pulsatile stimulation.
The key mechanism: CJC-1295 binds to GHRH receptors on pituitary somatotroph cells (the GH-producing cells), priming them for GH release. It does not directly trigger release — it prepares the pituitary for a stronger response when additional signals arrive.
| WHAT WE KNOW | A 2006 Journal of Clinical Endocrinology & Metabolism study by Teichman et al. showed CJC-1295 with DAC produced sustained increases in GH and IGF-1 levels lasting up to several days after a single injection, with a dose-dependent response. The pharmacokinetic profile — particularly the albumin-binding mechanism that extends half-life — is well characterized. CJC-1295 stimulates the pituitary’s own GH production, preserving the body’s feedback regulation rather than bypassing it. Body composition improvements including increased lean mass have been documented in research settings. |
| WHAT WE DON’T KNOW | Large-scale clinical trials specifically for age-related body composition in women are absent. Long-term safety and optimal cycling protocols in healthy aging populations are not established. The sustained GH elevation from the DAC version raises questions about receptor desensitization with extended use. The interaction between CJC-1295 and the hormonally shifted environment of menopause has not been specifically studied. |
| WHAT THAT MEANS | CJC-1295 has published human pharmacokinetic data and a well-characterized mechanism. The body composition applications are logical extensions of the documented GH and IGF-1 elevation it produces. The women-specific and long-term safety data is the significant gap. This is a compound with real clinical data that is being researched in a broader context than it was originally studied for. |
Ipamorelin — the selective amplifier
Ipamorelin is a different class of compound from Tesamorelin and CJC-1295. While those two are GHRH analogs — mimicking the signal from the hypothalamus — Ipamorelin is a ghrelin receptor agonist, a GH secretagogue that works through a separate receptor pathway. Ghrelin is the hormone produced by the stomach that also signals the pituitary to release GH.
Ipamorelin’s defining characteristic is its selectivity: it stimulates GH release without significantly elevating cortisol or prolactin — hormones that other GH secretagogues (particularly GHRP-6) tend to raise alongside GH. This selectivity makes it a cleaner signal — GH release without the cortisol and prolactin side effects that would undermine the metabolic goals.
Mechanistically, Ipamorelin also inhibits somatostatin — the body’s GH off-switch — which amplifies the GH pulse produced when combined with GHRH analogs like Tesamorelin or CJC-1295.
| WHAT WE KNOW | Ipamorelin’s selectivity for GH release without cortisol or prolactin elevation was documented in the original 1998 study by Raun et al. in the European Journal of Endocrinology — the finding that distinguishes it from earlier GH secretagogues. The ghrelin receptor mechanism is well characterized. The combination of Ipamorelin with GHRH analogs produces synergistic GH release greater than either compound alone — hitting two separate receptor pathways simultaneously. Body composition research has documented improvements in lean mass and fat mass in animal models. |
| WHAT WE DON’T KNOW | Human clinical trials for body composition specifically in aging populations are not published in the peer-reviewed literature. Long-term safety, optimal dosing, and cycling protocols in humans — particularly women in hormonal transition — are not established. The somatostatin inhibition mechanism and its long-term implications for pituitary function require further investigation. Whether the animal model body composition findings translate reliably to human outcomes is not confirmed. |
| WHAT THAT MEANS | Ipamorelin’s selectivity is its defining feature — the ability to amplify GH release through a separate receptor pathway without cortisol elevation is mechanistically important and distinguishes it from less targeted compounds. The human body composition evidence is earlier than for Tesamorelin. The combination rationale — three receptor pathways working simultaneously — is biologically coherent even where the human clinical evidence is incomplete. |
The IGF-1 question: what the research actually says
Any honest discussion of GH secretagogues requires addressing the IGF-1 and cancer question directly. IGF-1 is a growth factor — it promotes cell proliferation. The concern is whether elevated IGF-1 from GH stimulation could promote cancer growth.
The research on this question is nuanced and requires careful reading. The relevant distinction is between cancer promotion and cancer initiation. IGF-1 can promote the growth of existing cancer cells — this is a documented concern. For individuals with active malignancies, stimulation of the GH-IGF-1 axis is contraindicated without exception.
For healthy individuals, the picture is more complex. A 2019 review in Nature Reviews Endocrinology found that GH replacement therapy in GH-deficient patients did not increase cancer incidence and was associated with reduced cancer risk compared to untreated GH-deficient individuals — likely because adequate GH supports immune surveillance. The key variables are the baseline health of the individual, whether GH stimulation is producing physiological versus supraphysiological IGF-1 levels, and the duration of use.⁵
The honest position: the IGF-1 and cancer question is not resolved, and responsible use of GH secretagogues in any population requires ongoing monitoring of IGF-1 levels and appropriate medical oversight. This is not a question to dismiss — it is a question to take seriously and monitor carefully.
What this means for you
If your body composition has shifted after 40 in ways that do not respond to effort — if visceral fat has accumulated around your midsection, if muscle takes longer to build and disappears faster, if your metabolism feels fundamentally different — that shift is biological. It has mechanisms. It is not failure.
What the science supports clearly: the growth hormone decline of somatopause, compounded by estrogen withdrawal, produces specific and measurable changes in fat distribution, muscle protein synthesis, and metabolic function. Visceral fat is specifically resistant to mobilization when GH is low because of how GH receptor expression works in visceral adipose tissue. Sarcopenia accelerates in the perimenopausal period through documented hormonal mechanisms.
What the research is exploring: compounds that stimulate the pituitary’s own GH production — preserving pulsatile, self-regulating GH release rather than replacing it with external GH. Tesamorelin has the strongest clinical evidence base, including FDA approval. CJC-1295 has published human pharmacokinetic data. Ipamorelin has documented selectivity and a well-characterized mechanism. Together they address three separate receptor pathways simultaneously. The human body composition evidence — particularly for women in hormonal transition — is still maturing.
The IGF-1 question requires honest engagement, not dismissal. Anyone exploring these compounds should do so with appropriate medical oversight and IGF-1 monitoring.
Understanding the hormonal mechanics of body composition is where informed decisions start — not accepting that what is happening is inevitable.
